高雄榮民總醫院幽門螺旋桿菌抗藥性資料庫
胃腸科蔡峰偉醫師
幽門螺旋桿菌感染被認為是引起消化性潰瘍及胃癌的主因。而胃癌為現今全球癌症死亡之第二大病因，全世界每年有ㄧ百萬已上之人們因胃癌而死，根除幽門螺旋桿菌感染可以預防胃癌之產生。
在台灣，幽門螺旋桿菌感染率為54%，本院幽門螺旋桿菌醫療團隊證實︰此細菌之感染為引起台灣胃癌產生之罪魁禍首。為有效治療幽門螺旋桿菌感染，避免消化性潰瘍、胃癌及胃淋巴癌之產生，本科成立了幽門螺旋桿菌醫療團隊，並定期做幽門螺旋桿菌抗藥性監控，以做為台灣幽門螺旋桿菌研究之參考。目前醫界根據幽門螺旋桿菌除菌成效，有第一線除菌處方、第二線除菌處方及第三線除菌處方，本科每年對幽門螺旋桿菌感染患者在其除菌前採取胃黏膜檢體做細菌培養，以取得幽門螺旋桿菌的抗藥性結構。本科也同時收集台灣其他醫院發表之幽門螺旋桿菌的抗藥性資料供醫界研究參考。
資料來源
Feng-Woei Tsay, Ping-I Hsu, Kwok-Hung Lai, Gin-Ho Lo, Wen-Min Wan, Deng-Chyang Wu. 2007：Antibiotics resistances of H pylori in the 1st line, 2nd line and 3rd line eradication therapy in Taiwan. Annual Autumn Convention of the Gastroenterological Society of Taiwan, Taipei, Taiwan. P22.
Feng-Woei Tsay, Deng-Chyang Wu, Kwok-Hung Lai,Ping-I Hsu. 2012：Sequential changes in antibiotic resistances of Helicobacter pylori in Southern Taiwan from 2008 to 2012. Annual Autumn Convention of the Gastroenterological Society of Taiwan, Taipei, Taiwan. (In press)
Yang JC, Yang KC, Hsu CT, Wang CS, Kuo CF, Wang TH. A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy. J Microbiol Immunol Infect. 1999 Mar;32(1):1-8.
Poon SK, Chang CS, Su J, Lai CH, Yang CC, Chen GH, Wang WC. Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies.Aliment Pharmacol Ther. 2002 Feb;16(2):291-6.
Hu CT, Wu CC, Lin CY, Cheng CC, Su SC, Tseng YH, Lin NT. Resistance rate to antibiotics of Helicobacter pylori isolates in eastern Taiwan. J Gastroenterol Hepatol. 2007 May;22(5):720-3.
Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, Wang SS, Chen A, Hung WC, Graham DY. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection.Clin Gastroenterol Hepatol. 2010 Jan;8(1):36-41.e1. Epub 2009 Oct 3.